- ADENOSINE RECEPTOR BINDING COMPOUNDS
-
The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.
- -
-
Paragraph 00479
(2020/02/06)
-
- NOVEL PHOSPHODI ESTERASE INHIBITORS
-
The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein; and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further re
- -
-
Page/Page column 47-48
(2008/12/08)
-
- Cationic complexes of technetium-99m
-
The invention concerns cationic complexes of Technetium-99m with bidentate ligands (L), including complexes having the formulae [Tc(NO) X L2 ]+ and [Tc L3 ]+, which are of interest as heart imaging agents. The ligands are characterized by having the formula Y2 QZQY2, where each Q is phosphorus or arsenic, Z is a 2 or 3 carbon atom linking group, and at least one of the groups Y and Z includes at least one --COC--ether group.
- -
-
-